Harbin Jixianglong Biotech Co., Ltd.

Has Harbin Jixianglong Biotech Co., Ltd. received an FDA warning letter about GLP-1 drugs?

Yes. FDA issued Harbin Jixianglong Biotech Co., Ltd. a warning letter naming semaglutide and tirzepatide, dated May 1, 2026, with the FDA subject line “CGMP/API/Adulterated and Misbranded Drugs.” openFDA also lists 2 drug recall reports for the firm naming semaglutide.

FDA records in this index name Harbin Jixianglong Biotech Co., Ltd. from Feb 13, 2026 to May 1, 2026.

Type named in FDA records
API manufacturer
FDA warning letters
1
Drug recall reports
2
Drugs named
Semaglutide, Tirzepatide
Latest record
May 1, 2026

FDA warning letters

Later letters FDA listsLetter
May 1, 2026CGMP/API/Adulterated and Misbranded DrugsSemaglutide, TirzepatideNone listed by FDA as of Nov 15, 2026fda.gov

A warning letter states FDA’s view when it was issued; it is not a court finding, and the company may have responded since. The later-letters column repeats what FDA’s warning letter index lists for each letter.

FDA’s summary excerpts

Drug recalls

Record
Feb 13, 2026Semaglutide, For Rx compounding use only, packaged in a) 1g, NDC 84385-106-01; b) 5g, NDC 84385-106-02; c) 10g, NDC 84385-106-06; d) 25g, NDC 84385-106-03; ...CGMP Deviations This recall has been initiated due to failing to complete process validation and bacterial endotoxin method validation be...Class IIOngoingD-0380-2026
Feb 13, 2026Semaglutide, For Rx compounding use only, packaged in a) 1g, NDC 84385-106-01; b) 5g, NDC 84385-106-02; c) 10g, NDC 84385-106-06; d) 25g, NDC 84385-106-03; d...CGMP Deviations This recall has been initiated due to failing to complete process validation and bacterial endotoxin method validation be...Class IIOngoingD-0379-2026

FDA NDC listings

FDA’s NDC Directory files, read Nov 15, 2026, list 2 products naming retatrutide and tirzepatide under the labeler name “Harbin Jixianglong Biotech Co., Ltd.”, matched to this company page by exact name. Marketing categories as FDA gives them: BULK INGREDIENT (2).

84385-103Not givenRetatrutidePOWDERNot given100 g/100gBULK INGREDIENTJan 9, 2025None givenDec 31, 2026Unfinished drugs
84385-104Not givenTirzepatidePOWDERNot given100 g/100gBULK INGREDIENTMay 9, 2025None givenDec 31, 2027Unfinished drugs

FDA says: “Assignment of an NDC number does not in any way denote FDA approval of the product.” All GLP-1 NDC listings.

This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.